Article | October 20, 2021

COVID-19: A Wakeup Call For Clinical Trial Monitoring

iStock-1295693740-covid-coronavirus-vaccine-mrna

Clinical trials have two key goals: to prove the safety and efficacy of new therapeutics. Their success rests on the accurate collection, monitoring, and analysis of data. While today’s data collection is increasingly electronic, monitoring itself still largely occurs onsite, with monitors verifying source data by physically comparing the electronic data capture with the data in a patient’s medical history.

The recent COVID-19 virus highlights the vital importance of changing this model.

With governments everywhere asking people to practice social distancing or shelter in place, monitors are not able to get to sites—and clinical trial subjects aren’t able to get to investigators—creating a challenge for both data collection and monitoring. This threatens to derail trials at all stages, as well as potentially putting trial subjects in harm’s way. It doesn’t have to be this way.

VIEW THE ARTICLE!
Signing up provides unlimited access to:
Signing up provides unlimited access to:
  • Trend and Leadership Articles
  • Case Studies
  • Extensive Product Database
  • Premium Content
HELLO. PLEASE LOG IN. X

Not yet a member of Clinical Leader? Register today.

ACCOUNT SIGN UP X
Please fill in your account details
Login Information
ACCOUNT SIGN UP

Subscriptions

Sign up for the newsletter that brings you the industry's latest news, technologies, trends and products.

You might also want to: